iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
136 hedge funds and large institutions have $262M invested in iTeos Therapeutics in 2024 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 40 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.7% less ownership
Funds ownership: 100.16% → 93.46% (-6.7%)
9% less funds holding
Funds holding: 150 → 136 (-14)
30% less capital invested
Capital invested by funds: $373M → $262M (-$111M)
33% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 40
72% less call options, than puts
Call options by funds: $5.88M | Put options by funds: $21.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$20M |
| 2 |
JP Morgan Chase
New York
|
+$13.8M |
| 3 |
Citigroup
New York
|
+$7.16M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.15M |
| 5 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$18.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$16.4M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.39M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.85M |
| 5 |
6CM
683 Capital Management
New York
|
-$5.6M |
ITOS Hedge Fund Activity: Q4 2024 in Review
136 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2024, worth a combined $262M — down 30% from $373M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of ITOS and 27 opened new positions — a net loss of 13 holders — while 44 trimmed existing stakes and 50 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $20M. The largest seller was Tang Capital Management, cutting an estimated $18.8M.
- 136 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2024, down from 150 in Q3 2024.
- Funds reported $262M of iTeos Therapeutics stock for Q4 2024, down 30% quarter-over-quarter.
- 27 funds opened new iTeos Therapeutics positions in Q4 2024 and 40 closed out, a net change of -13 holders.
- The largest iTeos Therapeutics buyer in Q4 2024 was BVF Inc, an estimated $20M added.
- The largest iTeos Therapeutics seller in Q4 2024 was Tang Capital Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2024.